Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for MCK and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for MCK and 80,000+ other tickers.
See exactly how MCK's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MCK and 80,000+ other tickers.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical…
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the most recent trading session, McKesson (MCK) closed at $967.02, indicating a -2.6% shift from the previous trading day.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson Corp. stands out as an asset-heavy distributor poised to benefit from AI-driven prescription automation and expedited FDA rare-disease drug approvals. MCK's specialty and oncology segment, with 41% YoY profit growth and superior margins, insulates it from AI disintermediation risks affecting vertically integrated telehealth peers. Despite materially faster EPS growth (24% forward GAAP), MCK trades at only a modest premium (forward P/E 25.75x), with a PEG ratio of 0.55x, suggesting undervaluation.
Carnegie Investment Counsel raised its position in McKesson Corporation (NYSE: MCK) by 56.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,242 shares of the company's stock after acquiring an additional 1,525 shares during the quarter. Carnegie Investment Counsel's holdings in McKesson